Literature DB >> 16254308

ASCOT: a tale of two treatment regimens: is ASCOT-BPLA being hyped-up?

Peter D Burrill.   

Abstract

Mesh:

Substances:

Year:  2005        PMID: 16254308      PMCID: PMC1273493          DOI: 10.1136/bmj.331.7523.1022-a

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  5 in total

1.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Authors:  Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

2.  ASCOT: a tale of two treatment regimens.

Authors:  Claire McDougall; Adrian J B Brady; John R Petrie
Journal:  BMJ       Date:  2005-10-15

3.  Evidence that new antihypertensives are superior to older drugs.

Authors:  Jan A Staessen; Willem H Birkenhäger
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

4.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

Review 5.  Angiotensin receptor blockers and risk of myocardial infarction: systematic review.

Authors:  Michael A McDonald; Scot H Simpson; Justin A Ezekowitz; Gabor Gyenes; Ross T Tsuyuki
Journal:  BMJ       Date:  2005-09-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.